Is Bliss GVS Pharma the Best Stock in Its Sector? A Look at the Numbers

Bliss GVS Pharma CMP Rs 691 (24 Sep 2026). Market cap Rs 7,411 Cr. ROE 10.82%. P/E 52.28x versus Industry P/E 38.33x.

Updated: 24 Sept 2026 • 11:35 am

Posted by:

Is Bliss GVS Pharma the Best Stock in Its Sector? A Look at the Numbers

Quick Answer

Bliss GVS Pharma is one of the names investors compare when screening the Healthcare sector, built on a 10.82% return on equity and a P/E of 52.28x against an Industry P/E of 38.33x. Whether Bliss GVS Pharma is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.

Is Bliss GVS Pharma the best stock in its sector? The stock trades on the NSE at Rs 691 as of 24 September 2026, within its 52-week range of Rs 118.00 to Rs 728.00. Bliss GVS Pharma Ltd manufactures pharmaceutical formulations including suppositories and other specialised dosage forms.

Bliss GVS Pharma sits in the Healthcare sector, and its 10.82% ROE and 52.28x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector's Industry P/E benchmark.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

Table of Contents

About Bliss GVS Pharma

Bliss GVS Pharma Ltd manufactures pharmaceutical formulations including suppositories and other specialised dosage forms. It manufactures pharmaceutical formulations including suppositories and other specialised dosage forms, and the stock is trading close to its 52-week high after a sharp rally over the past year. At a market capitalisation of Rs 7,411 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Bliss GVS Pharma the Best Stock in Its Sector?

Bliss GVS Pharma makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 10.82% ROE with a 52.28x P/E against the sector's 38.33x Industry P/E. Bliss GVS Pharma's 52.28x P/E is above the 38.33x Industry P/E, a premium built on its specialised dosage form manufacturing and 10.82% ROE, though the stock's sharp rally toward its 52-week high is a factor worth weighing.

Metric	Bliss GVS Pharma
CMP (NSE)	Rs 691.10
52-Week High / Low	Rs 728.00 / Rs 118.00
Market Cap	Rs 7,411 Cr
P/E (TTM) vs Industry P/E	52.28x vs 38.33x
P/B	6.21
ROE	10.82%
EPS (TTM)	Rs 13.33
Dividend Yield	0.14%
Debt to Equity	0.02

Compare Bliss GVS Pharma Against Other Healthcare Sector Stocks

How Bliss GVS Pharma Compares Against Its Healthcare Sector Peers

The table below sets Bliss GVS Pharma against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Bliss GVS Pharma	7,411	52.28	10.82%	0.02
Bal Pharma	172	23.72	7.64%	1.94
Blue Jet Healthcare	11,075	47.15	18.22%	0.03
Peer average (2 companies)	-	35.44	12.93%	0.98

Against this peer set, Bliss GVS Pharma's 10.82% ROE is below the 12.93% peer average, and its P/E of 52.28x runs above the peer average of 35.44x. Bliss GVS Pharma's 52.28x P/E is above the 38.33x Industry P/E, a premium built on its specialised dosage form manufacturing and 10.82% ROE, though the stock's sharp rally toward its 52-week high is a factor worth weighing.

What Makes Bliss GVS Pharma Worth Watching in Healthcare

Near debt free: A debt to equity ratio of 0.02 gives Bliss GVS Pharma flexibility to invest in manufacturing capacity.
Specialised dosage form manufacturing: Manufacturing suppositories and other specialised dosage forms differentiates Bliss GVS Pharma from generic oral solid manufacturers.
Trading near its 52-week high: The stock has rallied sharply over the past year and is currently trading close to its 52-week high.

Bliss GVS Pharma Valuation: Is It Justified?

Bliss GVS Pharma's 52.28x P/E is above the 38.33x Industry P/E, a premium built on its specialised dosage form manufacturing and 10.82% ROE, though the stock's sharp rally toward its 52-week high is a factor worth weighing. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Bharat Bijlee the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Bliss GVS Pharma and other Healthcare sector stocks.

How to Track Bliss GVS Pharma Before You Invest

Before deciding whether Bliss GVS Pharma deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

Open the Univest Screener and search for Bliss GVS Pharma to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Bliss GVS Pharma earns a place in the best stock in its sector conversation on the strength of a 10.82% ROE and a P/E of 52.28x against a 38.33x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Is Bliss GVS Pharma the best stock in its sector?

Ans. Bliss GVS Pharma has a 10.82% ROE and trades at 52.28x P/E against a 38.33x Industry P/E, and compares below the peer average ROE of 12.93% in this article's named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Bliss GVS Pharma?

Ans. Bliss GVS Pharma was trading at Rs 691.10 on the NSE as of 24 September 2026, within its 52-week range of Rs 118.00 to Rs 728.00.

What sector does Bliss GVS Pharma belong to?

Ans. Bliss GVS Pharma is classified under the Healthcare sector on Univest.

How does Bliss GVS Pharma compare to its sector peers on P/E?

Ans. Bliss GVS Pharma's P/E of 52.28x is above the 35.44x average of the 2 named peers compared in this article.

What is Bliss GVS Pharma's return on equity?

Ans. Bliss GVS Pharma reported a return on equity of 10.82%, which is below the 12.93% average of its named peers in this comparison.

Should I invest in Bliss GVS Pharma based on its sector position?

Ans. Bliss GVS Pharma's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.